Patient Square Capital LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Patient Square Capital LP reported 11 stock positions worth $269.4 million. Its top holding was Roivant Sciences (ROIV) at 52.4% of the portfolio, followed by Liquidia (LQDA, 26.7%) and Cullinan Therapeutics (CGEM, 5.1%). Compared with Q2 2024, it opened 9 new positions. The biggest buy was a new position in Cullinan Therapeutics (CGEM).
- Most Recent 13F
- Q2 2026
- Location
- MENLO PARK, CA
- CIK
- 0001819257
- Portfolio Value
- $269.4M (Q3 2024)
- SEC Filing
- 0000950123-24-011804 ↗ filed Nov 14, 2024
Holdings Value
Holdings 11 stocks · $269.4M
| ROIV Roivant Sciences Ltd. | 52.38% | 12,228,465 | $141.1M | No change |
| LQDA Liquidia Corp. | 26.66% | 7,182,532 | $71.8M | No change |
| CGEM Cullinan Therapeutics Inc. | 5.12% | 824,705 | $13.8M | New |
| INSM Insmed Inc. | 4.65% | 171,704 | $12.5M | New |
| EYPT Eyepoint Inc. | 4.04% | 1,361,979 | $10.9M | New |
| NRIX Nurix Therapeutics Inc. | 2.72% | 325,789 | $7.3M | New |
| PHVS Pharvaris NV | 1.67% | 242,341 | $4.5M | New |
| NTLA Intellia Therapeutics Inc. | 0.98% | 128,569 | $2.6M | New |
| ELVN Enliven Therapeutics Inc. | 0.86% | 90,572 | $2.3M | New |
| OCUL Ocular Therapeutix Inc. | 0.76% | 235,498 | $2.0M | New |
| ATXS Astria Therapeutics Inc. | 0.16% | 39,422 | $434K | New |
Portfolio Sells Q2 2024 → Q3 2024
| None this quarter. | |||
Portfolio Buys Q2 2024 → Q3 2024
| CGEM Cullinan Therapeutics Inc. | New | 5.12% | +5.12 |
| INSM Insmed Inc. | New | 4.65% | +4.65 |
| EYPT Eyepoint Inc. | New | 4.04% | +4.04 |
| NRIX Nurix Therapeutics Inc. | New | 2.72% | +2.72 |
| PHVS Pharvaris NV | New | 1.67% | +1.67 |
| NTLA Intellia Therapeutics Inc. | New | 0.98% | +0.98 |
| ELVN Enliven Therapeutics Inc. | New | 0.86% | +0.86 |
| OCUL Ocular Therapeutix Inc. | New | 0.76% | +0.76 |
| ATXS Astria Therapeutics Inc. | New | 0.16% | +0.16 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $645.5M | ROIV, RVMD, MIRM, ABVX, ONC |
| Q1 2026 | 29 | $563.6M | ROIV, ARGX, INSM, ONC, COGT |
| Q4 2025 | 28 | $467.1M | ROIV, INSM, MIRM, ARGX, ONC |
| Q3 2025 | 24 | $373.9M | ROIV, INSM, EYPT, ABVX, CDTX |
| Q2 2025 | 19 | $277.4M | ROIV, INSM, ARGX, EYPT, LQDA |
| Q1 2025 | 19 | $241.7M | ROIV, INSM, LQDA, EYPT, OCUL |
| Q4 2024 | 20 | $267.4M | ROIV, LQDA, INSM, CGEM, EYPT |
| Q3 2024 | 11 | $269.4M | ROIV, LQDA, CGEM, INSM, EYPT |
| Q2 2024 | 2 | $215.4M | ROIV, LQDA |
| Q1 2024 | 2 | $234.8M | ROIV, LQDA |